Navigation Links
Pharmos Corporation to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
Date:5/14/2008

ISELIN, N.J., May 14 /PRNewswire-FirstCall/ -- Pharmos Corporation (Nasdaq: PARS) announced today that its President and Chief Financial Officer, S. Colin Neill, will present at the Rodman & Renshaw 5th Annual Global Healthcare Conference on Monday, May 19, 2008 at 5:15 PM Central Europe Daylight Time (GMT +2:00, or 11:15 AM Eastern Daylight Time). The conference is taking place May 19-20, 2008 at Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco.

In the presentation, Mr. Neill will provide an update on the Company's business and product pipeline. A webcast of the presentation will be available and archived for 90 days after the conference at http://www.wsw.com/webcast/rrshq13/pars. For additional information on this conference please visit http://www.rodmanandrenshaw.com/conferences?id=18.

About Pharmos Corporation

Pharmos Corporation is a biopharmaceutical company that discovers and develops novel therapeutics to treat a range of diseases of the nervous system, including disorders of the brain-gut axis, with a focus on pain/inflammation and autoimmune disorders. The Company's lead product, dextofisopam, is being studied in a Phase 2b clinical trial in patients with IBS. Dextofisopam has completed a Phase 2a IBS study in which it demonstrated a statistically significant effect compared to placebo on the primary efficacy endpoint of adequate relief (n=141, p=0.033) and was very well tolerated. A second program in Phase 2a involves a clinical trial of our NanoEmulsion cream drug delivery system to deliver the NSAID diclofenac topically in patients suffering from osteoarthritic knee pain. The Company's core proprietary technology platform focuses on discovery and development of synthetic cannabinoid compounds, especially CB2 receptor-selective (CB2-selective) agonists. PRS-639,058, the leading CB2-selective agonist, has demonstrated promising preclinical data in neuropathic pain. Various other CB2-selective compounds from Pharmos' pipeline are in preclinical studies targeting pain, multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease and other disorders.

Safe Harbor Statement

Statements made in this press release related to the business outlook and future financial performance of Pharmos, to the prospective market penetration of its drug products, to the development and commercialization of its pipeline products and to its expectations in connection with any future event, condition, performance or other matter, are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause results to differ materially from those set forth in these statements. Additional economic, competitive, governmental, technological, marketing and other factors identified in Pharmos' filings with the Securities and Exchange Commission could affect such results.


'/>"/>
SOURCE Pharmos Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pharmos Issues Letter to Shareholders
2. Pharmos Corporation Reports 2007 Third Quarter Results
3. Pharmos Corporation to Present at the 2007 RBC Capital Markets Healthcare Conference
4. Pharmos Corporation Announces President & COO Alan L. Rubino to Leave Company
5. Pharmos Corporation Announces Board and Management Changes
6. Pharmos Corporation Completes Initial Closing of Private Placement
7. Pharmos Corporation Reports 2008 First Quarter Results
8. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
9. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
10. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
11. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... May 03, 2016 , ... Flagship Biosciences, the leader in ... its Board of Directors. Dr. Gillett recently retired from Charles River Laboratories (CRL), ... Chief Scientific Officer. A board-certified veterinary pathologist, Dr. Gillett joined Charles River in ...
(Date:5/3/2016)... (PRWEB) , ... May 03, 2016 , ... According to ... , for definitive prostate cancer treatment, patients traditionally had two main treatment options: surgery ... plan would be made. , New technology has enabled doctors to administer higher ...
(Date:5/2/2016)... PHILADELPHIA, PA (PRWEB) , ... May 02, 2016 ... ... is proud to report on the pre-launch success of their revolutionary, veterinarian-designed product ... allowing cats to stalk, trap, and play with their food the way nature ...
(Date:4/29/2016)... CO (PRWEB) , ... April 29, 2016 , ... ... addressing the necessary fundamentals to transform technology into a viable company, CereScan’s CEO, ... growth. Mr. Kelley, a recognized leader and mentor in the Denver area ...
Breaking Biology Technology:
(Date:4/13/2016)... April 13, 2016  IMPOWER physicians supporting Medicaid patients ... a new clinical standard in telehealth thanks to a ... the higi platform, IMPOWER patients can routinely track key ... body mass index, and, when they opt in, share ... visit to a local retail location at no cost. ...
(Date:3/29/2016)... LegacyXChange, Inc. (OTC: LEGX ... Protect are pleased to announce our successful effort to ... of writing instruments, ensuring athletes signatures against counterfeiting and ... athletes on LegacyXChange will be assured of ongoing proof ... Bill Bollander , CEO states, "By inserting ...
(Date:3/22/2016)... and SANDY, Utah , ... which operates the highest sample volume laboratory in ... Genomics and UNIConnect, leaders in clinical sequencing informatics and ... launch of a project to establish the informatics infrastructure ... NSO has been contracted by the Ontario ...
Breaking Biology News(10 mins):